Mentioned in ?
References in periodicals archive ?
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
This hypothesis proved to be true by the discovery of the JAK2V617F mutation as the cause of the 3 main phenotypes of the MPNs essential thrombocythemia (ET), PV and myelofibrosis (MF).
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).
It was interesting to note that the frequency of JAK2 V617F mutation in essential thrombocythemia was much higher (70%) than that reported in the West, but was comparable in patients with PV and IMF (1,2,5,6).
Issues in the diagnosis and management of essential thrombocythemia.
Of those, four (67%) were in pregnancies complicated by essential thrombocythemia.
Essential thrombocythemia (ET) is a blood disorder in which the patient's bone marrow makes an excess of platelets.
The most common BCRJABL1-negative MPNs are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
22 per 100 000 for polycythemia vera and 24 per 100 000 for essential thrombocythemia in the US (13)] than some of the measures estimated here.
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Full browser ?